Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE

Clinical Immunology

Volumn 169, Issue , 2016, Pages 58-68

  Orme, Jacob J ^a   Du, Yong ^a,b   Vanarsa, Kamala ^a,b   Mayeux, Jessica ^a   Li, Li ^a   Mutwally, Azza ^a   Arriens, Cristina ^a   Min, Soyoun ^a   Hutcheson, Jack ^a   Davis, Laurie S ^a   Chong, Benjamin F ^a   Satterthwaite, Anne B ^a   Wu, Tianfu ^a,b   Mohan, Chandra ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Axl; Lupus; Macrophages; SLE

Indexed keywords

ADAM PROTEIN; ADAM10 ENDOPEPTIDASE; GI 254023; MATRIX METALLOPROTEINASE INHIBITOR; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE AXL; TAPI 0; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; GROWTH ARREST-SPECIFIC PROTEIN 6; ONCOPROTEIN; SIGNAL PEPTIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MACROPHAGE; MALE; MOUSE; NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; ANIMAL; C57BL MOUSE; CELL LINE; GENE EXPRESSION; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; YOUNG ADULT;

ADAM10 PROTEIN; ADAM17 PROTEIN; ADULT; ANIMALS; BLOTTING, WESTERN; CELL LINE; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES; MALE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84977622094     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.05.011     Document Type: Article

References (53)

1. [1] Kanta, H., Mohan, C., Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation. Genes Immun. 10 (2009), 390–396.
2. [2] Orme, J., Mohan, C., Macrophages and neutrophils in SLE—An online molecular catalog. Autoimmun. Rev. 11 (2012), 365–372.
3. [3] Cao, W.M., Murao, K., Imachi, H., Sato, M., Nakano, T., Kodama, T., Sasaguri, Y., Wong, N.C., Takahara, J., Ishida, T., Phosphatidylinositol 3-OH kinase–Akt/protein kinase B pathway mediates Gas6 induction of scavenger receptor A in immortalized human vascular smooth muscle cell line. Arterioscler. Thromb. Vasc. Biol. 21 (2001), 1592–1597.
4. [4] Fridell, Y., Jin, Y., Quilliam, L.A., Burchert, A., McCloskey, P., Spizz, G., Varnum, B., Der, C., Liu, E.T., Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol. Cell. Biol. 16 (1996), 135–145.
5. [5] Goruppi, S., Ruaro, E., Varnum, B., Schneider, C., Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras. Oncogene, 18, 1999, 4224.
6. [6] Hasanbasic, I., Cuerquis, J., Varnum, B., Blostein, M.D., Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 287 (2004), H1207–H1213.
7. [7] Tai, K., Shieh, Y., Lee, C., Shiah, S., Wu, C., Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1. Oncogene 27 (2008), 4044–4055.
8. [8] Zhang, Q.K., Boast, S., De Los Santos, K., Begemann, M., Goff, S.P., Transforming activity of retroviral genomes encoding Gag-Axl fusion proteins. J. Virol. 70 (1996), 8089–8097.
9. [9] Heng, T.S., Painter, M.W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S.J., Koller, D., Kim, F.S., Wagers, A.J., Asinovski, N., The immunological genome project: networks of gene expression in immune cells. Nat. Immunol. 9 (2008), 1091–1094.
10. [10] Lu, Q., Lemke, G., Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family. Science 293 (2001), 306–311.
11. [11] Scott, R.S., McMahon, E.J., Pop, S.M., Reap, E.A., Caricchio, R., Cohen, P.L., Earp, H.S., Matsushima, G.K., Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411 (2001), 207–211.
12. [12] Seitz, H.M., Camenisch, T.D., Lemke, G., Earp, H.S., Matsushima, G.K., Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells. J. Immunol. 178 (2007), 5635–5642.
13. [13] Weinger, J.G., Brosnan, C.F., Loudig, O., Goldberg, M.F., Macian, F., Arnett, H.A., Prieto, A.L., Tsiperson, V., Shafit-Zagardo, B., Loss of the receptor tyrosine kinase Axl leads to enhanced inflammation in the CNS and delayed removal of myelin debris during experimental autoimmune encephalomyelitis. J. Neuroinflammation, 8, 2011.
14. [14] Fiebeler, A., Park, J.-K., Muller, D.N., Lindschau, C., Mengel, M., Merkel, S., Banas, B., Luft, F.C., Haller, H., Growth arrest specific protein 6/Axl signaling in human inflammatory renal diseases. Am. J. Kidney Dis. 43 (2004), 286–295.
15. [15] Melaragno, M.G., Wuthrich, D.A., Poppa, V., Gill, D., Lindner, V., Berk, B.C., Corson, M.A., Increased expression of Axl tyrosine kinase after vascular injury and regulation by G protein–coupled receptor agonists in rats. Circ. Res. 83 (1998), 697–704.
16. [16] Nagai, K., Matsubara, T., Mima, A., Sumi, E., Kanamori, H., IEHARA, N., Fukatsu, A., Yanagita, M., Nakano, T., Ishimoto, Y., Gas6 induces Akt/mTOR-mediated mesangial hypertrophy in diabetic nephropathy. Kidney Int. 68 (2005), 552–561.
17. [17] Yanagita, M., Arai, H., Ishii, K., Nakano, T., Ohashi, K., Mizuno, K., Varnum, B., Fukatsu, A., Doi, T., Kita, T., Gas6 regulates mesangial cell proliferation through Axl in experimental glomerulonephritis. Am. J. Pathol. 158 (2001), 1423–1432.
18. [18] Sharif, M.N., Šošić, D., Rothlin, C.V., Kelly, E., Lemke, G., Olson, E.N., Ivashkiv, L.B., Twist mediates suppression of inflammation by type I IFNs and Axl. J. Exp. Med. 203 (2006), 1891–1901.
19. [19] Ekman, C., Jönsen, A., Sturfelt, G., Bengtsson, A.A., Dahlbäck, B., Plasma concentrations of Gas6 and sAxl correlate with disease activity in systemic lupus erythematosus. Rheumatology, 2011.
20. [20] Zhu, H., Sun, X., Zhu, L., Hu, F., Shi, L., Fan, C., Li, Z., Su, Y., Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus. Lupus, 2014.
21. [21] Zizzo, G., Guerrieri, J., Dittman, L.M., Merrill, J.T., Cohen, P.L., Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res. Ther., 15, 2013, R212.
22. [22] Zagórska, A., Través, P.G., Lew, E.D., Dransfield, I., Lemke, G., Diversification of TAM receptor tyrosine kinase function. Nat. Immunol., 2014.
23. [23] Morel, L., Blenman, K.R., Croker, B.P., Wakeland, E.K., The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 1787–1792.
24. [24] Morel, L., Croker, B.P., Blenman, K.R., Mohan, C., Huang, G., Gilkeson, G., Wakeland, E.K., Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 6670–6675.
25. [25] Subramanian, S., Tus, K., Li, Q.-Z., Wang, A., Tian, X.-H., Zhou, J., Liang, C., Bartov, G., McDaniel, L.D., Zhou, X.J., A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc. Natl. Acad. Sci. U. S. A. 103 (2006), 9970–9975.
26. [26] Chan, V.W., Meng, F., Soriano, P., DeFranco, A.L., Lowell, C.A., Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 7 (1997), 69–81.
27. [27] Helyer, B.J., Howie, J.B., Renal disease associated with positive lupus erythematosus tests in a cross-bred strain of mice. Nature, 197, 1963, 197.
28. [28] Mohan, C., Adams, S., Stanik, V., Datta, S.K., Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177 (1993), 1367–1381.
29. [29] Weischenfeldt, J., Porse, B., Bone marrow-derived macrophages (BMM): isolation and applications. Cold Spring Harb. Protoc., 2008 ((2008) pdb. prot5080).
30. [30] Fu, Y., Du, Y., Mohan, C., Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin. Immunol. 124 (2007), 109–118.
31. [31] Orme, J.J., Du, Y., Vanarsa, K., Mayeux, J., Li, L., Mutwally, A., Arriens, C., Min, S., Davis, L.S., Chong, B.F., Satterthwaite, A.B., Wu, T., Mohan, C., Axl is altered in SLE. Clin. Immunol., 2016 (Data in Brief).
32. [32] Gutwein, P., Schramme, A., Abdel-Bakky, M.S., Doberstein, K., Hauser, I.A., Ludwig, A., Altevogt, P., Gauer, S., Hillmann, A., Weide, T., Jespersen, C., Eberhardt, W., Pfeilschifter, J., ADAM10 is expressed in human podocytes and found in urinary vesicles of patients with glomerular kidney diseases. J. Biomed. Sci., 17, 2010.
33. [33] Neubauer, A., Fiebeler, A., Graham, D., O'Bryan, J., Schmidt, C., Barckow, P., Serke, S., Siegert, W., Snodgrass, H., Huhn, D., Expression of Axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis. Blood 84 (1994), 1931–1941.
34. [34] Abbas, A.R., Wolslegel, K., Seshasayee, D., Modrusan, Z., Clark, H.F., Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One, 4, 2009, e6098.
35. [35] Budagian, V., Bulanova, E., Orinska, Z., Duitman, E., Brandt, K., Ludwig, A., Hartmann, D., Lemke, G., Saftig, P., Bulfone-Paus, S., Soluble Axl is generated by ADAM10-dependent cleavage and associates with Gas6 in mouse serum. Mol. Cell. Biol. 25 (2005), 9324–9339.
36. [36] O'Bryan, J.P., Fridell, Y.-W., Koski, R., Varnum, B., Liu, E.T., The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by Proteolytic cleavage. J. Biol. Chem. 270 (1995), 551–557.
37. [37] Wilhelm, I., Nagyőszi, P., Farkas, A.E., Couraud, P.-O., Romero, I.A., Weksler, B., Fazakas, C., Dung, N.T.K., Bottka, S., Bauer, H., Bauer, H.-C., Krizbai, I.A., Hyperosmotic stress induces Axl activation and cleavage in cerebral endothelial cells. J. Neurochem. 107 (2008), 116–126.
38. [38] Van Der Voort, R., Van Lieshout, A.W.T., Toonen, L.W.J., Slöetjes, A.W., Van Den Berg, W.B., Figdor, C.G., Radstake, T.R.D.J., Adema, G.J., Elevated CXCL16 expression by synovial macrophages recruits memory T cells into rheumatoid joints. Arthritis Rheum. 52 (2005), 1381–1391.
39. [39] Kieseier, B.C., Pischel, H., Neuen-Jacob, E., Tourtellotte, W.W., Hartung, H.-P., ADAM-10 and ADAM-17 in the inflamed human CNS. Glia 42 (2003), 398–405.
40. [40] Saitoh, H., Leopold, P.L., Harvey, B.-G., O'Connor, T.P., Worgall, S., Hackett, N.R., Crystal, R.G., Emphysema mediated by lung overexpression of ADAM10. Clin. Transl. Sci. 2 (2009), 50–56.
41. [41] Huovila, A.-P.J., Turner, A.J., Pelto-Huikko, M., Kärkkäinen, I., Ortiz, R.M., Shedding light on ADAM metalloproteinases. Trends Biochem. Sci. 30 (2005), 413–422.
42. [42] Wu, T., Xie, C., Wang, H.W., Zhou, X.J., Schwartz, N., Calixto, S., Mackay, M., Aranow, C., Putterman, C., Mohan, C., Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J. Immunol. 179 (2007), 7166–7175.
43. [43] Yamamoto, S., Higuchi, Y., Yoshiyama, K., Shimizu, E., Kataoka, M., Hijiya, N., Matsuura, K., ADAM family proteins in the immune system. Immunol. Today 20 (1999), 278–284.
44. [44] Pruessmeyer, J., Ludwig, A., The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin. Cell Dev. Biol. 20 (2009), 164–174.
45. [45] Sosic, D., Richardson, J.A., Yu, K., Ornitz, D.M., Olson, E.N., Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112 (2003), 169–180.
46. [46] Cervera, R., Khamashta, M.A., Font, J., Sebastiani, G.D., Gil, A., Lavilla, P., Mejía, J.C., Aydintug, A.O., Chwalinska-Sadowska, H., de Ramón, E., Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 82 (2003), 299–308.
47. [47] Baechler, E.C., Batliwalla, F.M., Karypis, G., Gaffney, P.M., Ortmann, W.A., Espe, K.J., Shark, K.B., Grande, W.J., Hughes, K.M., Kapur, V., Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003), 2610–2615.
48. [48] Bennett, L., Palucka, A.K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., Pascual, V., Interferon and Granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197 (2003), 711–723.
49. [49] Dall'Era, M.C., Cardarelli, P.M., Preston, B.T., Witte, A., Davis, J.C., Type I interferon correlates with serological and clinical manifestations of SLE. Ann. Rheum. Dis. 64 (2005), 1692–1697.
50. [50] Tilg, H., New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 112 (1997), 1017–1021.
51. [51] Banchereau, J., Pascual, V., Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25 (2006), 383–392.
52. [52] Williams, J.M., Zhang, J., North, P., Lacy, S., Yakes, M., Dahly-Vernon, A., Roman, R.J., Evaluation of metalloprotease inhibitors on hypertension and diabetic nephropathy. Am. J. Physiol. Ren. Physiol., 300, 2011, F983.
53. [53] Orme, J., Mohan, C., Macrophage subpopulations in systemic lupus erythematosus. Discov. Med. 13 (2012), 151–158.